"Kerastem reports month topline data from its clinical study STYLE a  patient phase II US multicenter randomized singleblinded and controlled clinical trial investigating Kerastems therapy in patients with early stage hair loss.  The Kerastem therapy is a onetime treatment that utilizes adipose fat derived regenerative cells combined with purified fat delivered to the affected area of scalp.  Low dose Adipose Derived Regenerative Cells ADRCs  Puregraft fat treatment group achieved a statistically significant increase in mean terminal hair count when compared to control in males with early stage hair loss Norwood Grades IIII. An average increase of  terminal hairs per cm of scalp was observed corresponding to a  increase p  . from baseline.   All treatment arms of STYLE were safe with no serious adverse events reported. The Kerastem team has successfully identified a treatment that stimulates hair growth in people with early stage hair loss stated Brad Conlan CEO of Kerastem.  There are over  million people with early stage hair loss in the United States alone.  Kerastem is poised to disrupt this market based upon the results from STYLE and is actively signing and exploring distribution relationships outside of the United States.  We are thrilled about the STYLE data and what it means for patients with early stage hair loss who have had very few treatment options to date.  KERASTEM SUPERIOR TO OTHER CELL BASED TREATMENT CURRENTLY AVAILABLE According to Dr. Eric Daniels Kerastems Chief Medical Officer STYLE indicates that dosing and tissue preparation are essential to achieving a successful outcome.  Added Dr. Daniels We were very pleased to see the positive results from the low dose arm and were surprised that the high dose ADRCs  Puregraft fat treatment group along with the fat alone group observed a reduction or no change respectively in terminal hair counts. Stated otherwise dosing and tissue purity matter. To understand the STYLE results in contextthe low dose treatment group had an average increase of  hairs per cm of scalp which corresponds to an increase of  hairs per  cm of treated scalp.  While the average hair transplant today is between  to  transplanted hairs patients with early hair loss are very often not candidates for hair transplantation.  Kerastem therapy represents a new option.  The therapy utilizes patented medical device technology to deliver a consistent cell therapy output enabling appropriate dosing. ANDROGENETIC ALOPECIA MARKET SIZE Hair loss affects more than  million men and  million women and in the United States alone.  The global hair loss treatment market generates more than  Billion annually and currently has limited options for men grades IIII and women grades III with early stage hair loss. ABOUT KERASTEM Kerastem is the leader in the development and commercialization of cellbased approaches to hair growth. The company is a wholly owned subsidiary of Bimini Technologies. The Bimini portfolio also includes Puregraft the worlds leading fat transfer solution. SOURCE Kerastem"